Lymphocyte responses exacerbate angiotensin II-dependent hypertension.
Activation of the immune system by ANG II contributes to the pathogenesis of hypertension, and pharmacological suppression of lymphocyte responses can ameliorate hypertensive end-organ damage. Therefore, to examine the mechanisms through which lymphocytes mediate blood pressure elevation, we studied ANG II-dependent hypertension in scid mice lacking lymphocyte responses and wild-type controls. Scid mice had a blunted hypertensive response to chronic ANG II infusion and accordingly developed less cardiac hypertrophy. Moreover, lymphocyte deficiency led to significant reductions in heart and kidney injury following 4 wk of angiotensin. The muted hypertensive response in the scid mice was associated with increased sodium excretion, urine volumes, and weight loss beginning on day 5 of angiotensin infusion. To explore the mechanisms underlying alterations in blood pressure and renal sodium handling, we measured gene expression for vasoactive mediators in the kidney after 4 wk of ANG II administration. Scid mice and controls had similar renal expression for interferon-gamma, interleukin-1beta, and interleukin-6. By contrast, lymphocyte deficiency (i.e., scid mice) during ANG II infusion led to upregulation of tumor necrosis factor-alpha, endothelial nitric oxide synthase (eNOS), and cyclooxygenase-2 (COX-2) in the kidney. In turn, this enhanced eNOS and COX-2 expression in the scid kidneys was associated with exaggerated renal generation of nitric oxide, prostaglandin E(2), and prostacyclin, all of which promote natriuresis. Thus, the absence of lymphocyte activity protects from hypertension by allowing blood pressure-induced sodium excretion, possibly via stimulation of eNOS- and COX-2-dependent pathways.
Crowley
Steven D
SD
Department of Medicine, Duke University Medical Center, Durham, NC, USA. crowl004@mc.duke.edu
Song
Young-Soo
YS
Lin
Eugene E
EE
Griffiths
Robert
R
Kim
Hyung-Suk
HS
Ruiz
Phillip
P
D000804:Angiotensin II / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D006332:Cardiomegaly / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D003433:Crosses, Genetic; D018450:Disease Progression; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000502:physiology; D006973:Hypertension / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000293:injuries / Q000503:physiopathology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D051379:Mice; D008809:Mice, Inbred C3H; D016513:Mice, SCID / Q000276:immunology; D009929:Organ Size / Q000187:drug effects; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics
D012333:RNA, Messenger; D000804:Angiotensin II